Heron Therapeutics (NASDAQ:HRTX) Stock Crosses Above 200 Day Moving Average - Should You Sell?

Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.82 and traded as high as $1.91. Heron Therapeutics shares last traded at $1.79, with a volume of 651,612 shares.

Analysts Set New Price Targets

HRTX has been the topic of a number of research analyst reports. StockNews.com cut shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, January 29th. Needham & Company LLC restated a "buy" rating and set a $4.00 price target on shares of Heron Therapeutics in a report on Wednesday, December 4th.

Heron Therapeutics Price Performance

The stock has a market cap of $252.49 million, a price-to-earnings ratio of -9.22 and a beta of 1.60. The firm's fifty day moving average price is $1.64 and its two-hundred day moving average price is $1.78.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.03). The firm had revenue of $32.81 million for the quarter, compared to analyst estimates of $36.40 million. During the same period last year, the company posted ($0.17) earnings per share. On average, equities research analysts anticipate that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Institutional Trading of Heron Therapeutics

Several hedge funds have recently bought and sold shares of the business. Argent Advisors Inc. acquired a new position in Heron Therapeutics during the fourth quarter worth $31,000. CM Management LLC increased its position in shares of Heron Therapeutics by 40.0% during the fourth quarter. CM Management LLC now owns 700,000 shares of the biotechnology company's stock worth $1,071,000 after acquiring an additional 200,000 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Heron Therapeutics in the 4th quarter worth about $208,000. Charles Schwab Investment Management Inc. lifted its position in Heron Therapeutics by 0.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company's stock valued at $1,692,000 after acquiring an additional 9,418 shares in the last quarter. Finally, Anfield Capital Management LLC boosted its stake in Heron Therapeutics by 5.6% during the 4th quarter. Anfield Capital Management LLC now owns 118,976 shares of the biotechnology company's stock valued at $182,000 after purchasing an additional 6,264 shares during the last quarter. Institutional investors and hedge funds own 80.01% of the company's stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.